Phase I Study of SU011248 [sunitinib] in Combination With Paclitaxel/Carboplatin in Patients With Advanced Solid Malignancies.
Latest Information Update: 25 Nov 2009
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Sunitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 21 Nov 2009 New source identified and integrated (M.D. Anderson Cancer Center record 2006-0414).
- 21 Nov 2009 Planned number of patients changed from 50 to 72 as reported by M.D. Anderson Cancer Center record.
- 14 Jul 2009 Actual patient number (43) added as reported by ClinicalTrials.gov.